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ABSTRACT 
It’s been nearly 100 y of effort to study the organization and role of the blood brain-barrier and still, we strive to find better techniques to overcome this 
barrier to deliver the drugs to the brain effectively with reduced systemic side effects. The advances in nanotechnology have given newer horizons in 
achieving this goal since the nano-scaled systems can modify an existing drug to have a high degree of sensitivity to the physiological conditions and 
specificity to reach the target organ. Among the various nanocarriers, dendrimers owing to their unique physical and chemical characteristics, represent 
a potential therapeutic tool in biomedical and pharmaceutical science. Dendrimers, an established polymeric nanocarrier system of the time, can deliver 
both drugs and genetic material and are being extensively studied to target the brain. The surface modification of dendrimers can reduce their innate 
toxicity problems and increase the therapeutic efficacy of brain disorders. This review article is an attempt to update on the potential of dendrimers 
explored in the past five years as a drug delivery avenue that can be considered as a promising solution in the management of a wide range of disorders 
affecting the central nervous system, including neoplastic, degenerative, and ischemic conditions. The following search criteria were used to expand the 
review article with the keywords dendrimers, novel drug delivery, nanoparticles, site-specific drug delivery etc. 
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INTRODUCTION 
The diseases affecting the brain are numerous, including Alzheimer’s 
disease, Huntington’s disease, Parkinson’s disease, head trauma, 
amyotrophic lateral sclerosis (ALS), brain cancer, epilepsy, and 
stroke. The prevalence of these diseases is increasing at an alarming 
rate. It accounts for 11% of the total world population, which 
represents over 1.5 billion people globally. The threat worsens as 
the global burden of CNS disorder is expected to increase to 14.7% 
by 2020 with the change in population demographics [1]. 
The treatment of brain disorders persists as a daunting challenge 
amidst the advances in medical technology because of the natural 
barrier in the brain. The barrier exists at three interfaces namely the 
blood-brain barrier, which occurs at the blood vessels of the brain, 
the blood-cerebrospinal fluid barrier at the choroid plexus, and the 
blood arachnoid layer of the meninges. These barriers are absolutely 
a boon to keep the brain and nervous system healthy by strictly 
prohibiting the entry of any unwanted molecules but a bane when it 
comes to preventing the therapeutic agents to enter the brain and 
act in favor of treating the ailment [2]. 
Nanotechnology offers great promise for revolutionizing medical 
imaging, diagnostics, and therapeutics [3]. The design and 
development of innovative nanocarriers made of lipids or polymers as 
drug delivery systems have been the main input of nanotechnology in 
pharmaceutics, which helps to carry the drug introduced through 
various invasive or noninvasive routes in the body in a controlled 
manner from the site of administration to the therapeutic target [4]. 
The various nanocarriers used for CNS delivery include polymeric 
nanoparticles, Solid Lipid Nanoparticles, liposomes, micelles, 
nanoemulsions, nanogels, nanosuspensions, dendrimers, Carbon 
Nanotubes and fullerenes. Among them, dendrimers owing to their 
unique characteristics represent a potential therapeutic tool in 
biomedical and pharmaceutical science. Low dispersity, high 
functionality, high penetration ability, high density, and peripheral 
functional group reactivity are some of the featured advantages [5]. 
All features of the dendrimer nanoparticle are modifiable for 
delivery purposes, including the core, the branching pattern, the 
surface characteristics, and the binding and releasing characteristics 
to target ligands [6]. This review will mainly focus on the recent 
therapeutic advances using dendrimers for brain delivery of drugs 
and nucleic acids for the various CNS disorders. 
Challenges of drug delivery to the brain 
The brain is a highly sensitive organ with a well-defined neuronal 
homeostatic environment, which is crucial for maintaining the 
functionality of the whole body. The brain barriers, including the 
blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier 
(B-CSFB) along with its neurovascular unit (NVU) protect the brain 
from potentially harmful blood-borne compounds. Like any other 
chemical entity, the drug molecules are also foreign substances for 
these barriers and hence prevent its entry into the brain tissues, 
which makes the treatment of CNS disorders an unresolvable puzzle 
despite the enormous advances in CNS research [7]. 
The factors affecting the restricted entry of the drug moieties into 
the brain can be classified into two.  
1. The anatomical features of the brain barriers. 
2. The drug-related properties and metabolic interactions in the 
body [8]. 
Brain barriers 
The BBB is an inimitable physiological barrier that firmly isolates 
the brain from the circulating blood and some of the following 
factors determine its reluctance to allow the entry of CNS drugs [9]. 
• The BBB provides strong resistance to the movement of ions, with 
trans endothelial electrical resistance (TEER) around 1500 Ω cm2, 
which is about 100 times higher than that for peripheral 
microvessels (3-30Ωcm2)
• The presence of efflux pumps and the additional enzymatic 
aspects in the BBB which serves to protect the brain, presents an 
active barrier [12]. 
 [10]. This causes a “passive” physical 
barrier which is due to reduced aqueous-based paracellular 
diffusion mechanisms which are found in other body parts [11]. 
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• The BBB Endothelial cells are characterized by increased 
mitochondrial content, minimal pinocytotic activity, and lack of 
fenestrations [13]. The restricted paracellular permeability of the 
capillary endothelial cell is attributed to the two intercellular 
molecular binding systems-the junction and the tight junction [14]. 
The B-CSFB is another protective shield that prevents the entry of 
molecules from the blood to the brain parenchyma containing 
interstitial fluid and CSF which is found at the arachnoid membrane 
and choroid plexus. The B-CSFB owing to the choroid plexus 
passively regulates the passage of drugs into CSF by the presence of 
tight junctions and actively by its organic acid efflux transporters 
and at arachnoid membrane, this barrier is passively impermeable 
to hydrophilic substances to a great extent [15]. 
Drug-related factors 
Not only are the specialized anatomy of the brain parenchyma and 
barrier properties the sole reason hampering the adequate 
distribution of CNS drugs into the brain, but the physiological 
mechanisms and the specific drug properties also determine the 
concentrations of a drug within a specific region of the CNS [16]. A 
drug administered into the body has to undergo all the basic 
pharmacokinetic mechanisms such as transport from the site of 
administration into the systemic circulation (except for compounds 
administered intravenously), the drug then distributes across the 
body, further subjected to metabolism/biotransformation by different 
enzymes and finally eliminated from the body. A drug should possess 
optimum lipophilicity and solubility to be well absorbed into the body 
[17, 18]. But on increasing the lipophilicity of the drug tending to 
increase the permeability across the membranes it leads to a higher 
rate of metabolic clearance and stronger binding to plasma proteins 
[19]. The optimum lipophilicity required to facilitate maximum 
bioavailability needs to be carefully determined in the drug delivery 
process, particularly for CNS drugs in which the lipophilicity of the 
drug is the major governing factor that allows them to cross the BBB. 
The size of the drug and its charge are also prime factors where 
molecular weight greater than 400-500 Da do not cross the BBB (with 
some exceptions) in pharmacologically significant amounts [20]. 
To overcome these challenges, currently, there are various strategies 
of drug delivery to the brain. It is well classified with examples of 
application in table 1.
 





 Different type of strategies  Examples  References 
I) Chemical delivery 
system 
 Lipid-mediated transport 
(Lipidization of small molecules) 
- Diacetylated form of morphine  
[21] 
   Prodrug Approach - Zidovudine (AZT), ganciclovir, benzylbenicillin estradiol. [22-27] 
   Lock-In System - 1,4-dihydrotrigonelline-Trigonelline system 
pyridinium salt redox system 
[28, 29] 
   Adsorptive-Mediated 
Transcytosis 
- Aclarubicin-Loaded Cbsa-Np For Glioma Chemotherapy [30] 
   Carrier-Mediated Transport - L-DOPA, Gabapentin, Mephalan via LAT1 neutral amino acid 
carrier 
[31] 
II) Biological delivery 
systems 
 
 Receptor-Mediated Transport - Transferrin Receptor (TfR): Human TfR fused to iduronate 
2-sulfatase (IDS): JR-141 
- Insulin receptor (IR): HIRMAb complexed 
with N-sulfoglucosamine sulfohydrolase (SGSH): 
HIRMAb-SGSH. 
- Low-Density Lipoprotein Receptor (LDLR): Angiopep-2 
combined with antitumor drug paclitaxel 
[32] 
   Active Efflux Transport  - In combination with 3rd [33]  generation Pgp inhibitors like 
tariquidar, zosuquidar, laniquidar 
   Peptide Vector Strategies - ANG1005, p97, VH0445 [34] 






- Mannitol, arabinose 
- hyperosmolar solutions of lactamide, saline, urea 
[35, 36] 
   Biochemical disruption by 
administration of Vasoactive 
Substances 
- Arachidonic acid, Leukotriene, Bradykinin, Histamine, 
Serotonin, Polyamines. 
[37] 
   BBB Disruption by Alkylglycerols 1-O-pentylglycerol, 2-O-hexyldiglycerol [38] 
IV) Molecular trojan 
horses for brain 
drug delivery 
 Genetically engineered proteins 
(peptidomimetics) 
- To carry peptides like BDNF, FGF2,VIP and plasmid DNAs 
like luciferase gene, TH gene, antisense gene 
[39] 
V) Novel Drug Delivery 
Approach 
 
 Via Catheters and Pumps.  [40] 
  Microspheres - Resperidol® [41]  consta, Parlodel® LAR 
  Biodegradable Wafers - Intracranial placement of Gliadel wafer [42] 
  From colloidal drug carrier 
systems 
 [43, 44] 
   From Microchips  [45] 
VI) Other alternative 
Routes/Methods. 
 
 Intranasal Drug Delivery  - Stadol NS®, Stimate NS, Syneral® Nasal Solution, Zomig 
Nasal Spray 
[46] 
 Convection-Enhanced Diffusion. - Delivery of GDNF in Parkinson’s disease, molecularly 
targeted recombinant chimera cytotoxic fusion proteins in 
anti-GBM therapy 
[47] 




All these approaches for delivering drugs to the brain have shown 
promising results from the respective studies done but have their 
own limitations. For example, the invasive techniques including 
disrupting the blood-brain barrier by using hypertonic solutions of 
mannitol, arabinose, urea, or synthetic analog of Bradykinin, namely 
RMP7, or creating a temporary increase in the vascular permeability 
with agents such as histamine and vasoactive peptides allow direct 
entry of the drug into the brain; it is accompanied by major side 
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effects such as damage to the neurons, inflammatory reactions, etc. 
which restricts the use of the invasive technique as an unsafe 
method to CNS disorder treatment [49]. Intraventricular route of 
administration can provide only some degree of penetration to the 
parenchyma and compare to the target cells; there is more of 
ependymal cell uptake in the ventricle [50]. Other convection 
technologies like a focused ultrasound of low intensity in 
combination with microbubbles or implants can provide localised 
delivery of drugs but it becomes inefficient to treat disorders that 
affects multiple areas of the brain, which is the case with most of the 
CNS disorders [51]. Thus finding a drug delivery system that can 
deliver the drugs to the target cells precisely and adequately is the 
need of the hour. 
From the past few years, various nanosystems have been 
investigated for meeting the need for effective therapies for 
neurological diseases. The vast research happening in the field of 
nanotechnology has led to a broader understanding of the 
mechanism of nanoparticle uptake to the brain [52]. Among the 
various nanomaterials so far developed, dendrimers show a huge 
potential as an excellent nanocarrier owing to their well-defined, 
globular, highly branched and controllable nanostructural features, 
which are unique to them and the terminal groups present can be 
functionalized with different ligands having multivalency similar to 
the chemical groups present in different biological systems [53]. In 
addition to being explored as promising carriers of chemical drugs, 
therapeutic nucleic acids, proteins and peptides, they are also 
functional as macromolecular contrast agents and biosensor 
platforms for CNS therapies, imaging, and diagnosis [54]. All these 
possibilities offered by dendrimers upraise them to be smart 
nanocarriers in the future endeavors in drug delivery systems [55]. 
Dendrimers 
Dendrimers are three-dimensional polymeric materials composed of 
repeatedly branched monomeric units called dendrons, which 
coalesce to form a highly symmetrical structure [56]. The dendrons 
are single chemically distinct groups attached by chemical bonds to 
the center of the dendrimer [57]. The term dendrimer originated 
from the Greek word “dendron” which means a tree-like structure 
and “meros” which means part [58]. Dendrimers consists of a central 
core to which repeated branching cycles, commonly referred to as 
generations, are added. Each generation is assigned a generation 
number indicating the number of branching reactions performed 
onto the core molecule [59]. The ends of these branches form the 
multivalent surface, which can be specialized for specific functions. 




Fig. 1: The basic structure of a dendrimer with three generations [60] 
 
The surface functionalization of dendrimers is usually carried out to 
reduce its rapid clearance by the reticuloendothelial system and its 
toxicity issues caused by the interaction between the 
amine-terminated groups and the cell membrane. Surface 
functionalization improves the transfection efficiency and the 
specificity of dendrimers. The increased biocompatibility and 
controlled release behavior based on stimuli responsiveness of 
functionalized dendrimers enhance its therapeutic efficiency [61]. A 
relevant finding was done by Vidal F et al. (2016) about the correlation 
of surface characteristics and their neuronal internalization process 
and its rate of internalization. They studied on four different variations 
of surface functionalization of a generation 4 PAMAM dendrimer (G4) 
as follows: an unmodified group, 50% amino surface groups modified 
with neutral polyethylene glycol groups (PP50), 30% amino groups 
with anionic acrylate groups (PAc) and 25% with folic groups (PFO). 
From the confocal microscopy studies, it was understood that only the 
unmodified and PFO dendrimers are uptaken by the neuronal 
hippocampus cells accounted for the change in surface charge density 
of PP50 and PAc modified dendrimers leading to the complete 
blockade of its cellular internalization. The surface modification also 
affects the internalization pathway, which was studied from 
colocalization analysis. Thus, the surface modification should be done 
based on thorough knowledge as it influences the neuronal uptake 
following its release from the nanocarrier [62]. 
Large-sized dendrimers are preferred for the fact that they can 
increase the dendrimer accumulation in the brain by slowing down 
the clearance rate and prolonging systemic circulation without 
losing their inborn capacity to target the stimulated microglia and 
damaged neurons. Zhang F et al. studied the influence of the size of 
dendrimer on brain uptake by investigating the pharmacokinetic 
distribution in a clinically-significant canine model of HCA-triggered 
brain damage. They found out that the Generation 6 (G6) of 
Polyamidoamine (PAMAM) dendrimers with-OH ending groups had 
a hydrodynamic diameter around 6.7 nm that lied on the verge of 
the range of renal filtration and was approximately 1.5-fold greater 
than G4 dendrimers. Both dendrimers had comparable surface 
characteristics (neutral and hydrophilic) and they were not likely to 
attach to plasma serum proteins. However, the slight increase in the 
size of G6 dendrimers could potentially increase the circulation 
period after its systemic administration without changing the most 
important renal clearance pathway [63]. 
Dendrimers have a multifunctional capability ranging from 
enhancing solubility, dissolution, gastrointestinal tract (GIT) 
permeability, stability [64] to promoting better bioavailability, 
allows multiple drug entrapment, and controlled delivery [64-67]. 
There are three main sites for drug entrapment in the dendrimer 
architecture, which is explained in table 2.
 
Table 2: Different sites for drug entrapment in the dendrimer 
Site  Mechanism  References 
1) Void spaces Entrapment of molecules [68] 
2) Branching points Hydrogen bonding [68] 
3) Surface groups Charge-charge interactions [68] 
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The science of dendrimers can be considered as a combination of 
molecular and polymer chemistry. The step-by-step-controlled 
reactions of synthesis makes it a part of molecular chemistry, 
whereas the repetitive structure of dendrons (monomers) shows the 
role of it in polymer chemistry [69, 70]. Dendrimers can be 
synthesized by the following methods:  
1. Divergent approach: This is one of the earliest methods where 
the synthesis begins from the core and extend towards the 
periphery by the repetition of the two basic reactions a) coupling of 
the monomer. 
b) Transforming the monomer end group to form a new coupling 
site for the next monomer [71]. 
2. Convergent approach: This method involves the synthesis of the 
dendrimer from the periphery to its core by the one to one coupling 
of the dendritic segments. This was first described by Hawker and 
Frechet in 1989–1990 [72]. 
3. Double exponential method: This process involves the 
accumulation with a single trifunctional monomer in the form 
Am(Bm)2, 
4. Hyper core/Hyper monomer approach: In this method, the first 
step is to synthesis the hyper monomer with low-generation 
dendrons having protected terminal groups by the convergent 
approach. These monomers are joined to a multifunctional core via 
their focal point which is called a hyper-core and the terminal 
groups of the resultant low-generation dendrimer are deprotected. 
Finally, all the hyper monomers, which are either indistinguishable 
to the preceding one or different, are reacted with this hyper-core to 
result in the formation of an anticipated higher generation 
dendrimer [74, 75]. 
which has orthogonally protected functional groups. The 
number of repeat units per dendrimer is in accordance to a double 
exponential function in terms of generation, n. There will be a 
selective removal of the protecting groups on Am in one portion and 
on Bm in the second portion during the repetitive process, and the 
two monoprotected intermediates are subsequently coupled in a 
proper stoichiometric ratio [73]. 
5. Orthogonal coupling strategy: It is a rapid method of synthesis 
that can exclude the deprotection steps or the intermediate 
activation steps leading to an accelerated growth of dendrimers. It 
involves the chemoselective reaction between the monomers ABn 
and CDn, 
6. Click chemistry: Various click reactions including 
Copper-Assisted Azide-Alkyne Cycloaddition (CuAAC), Thiol-ene and 
Thiol-yne Click Reactions (TEC TYC), and Diels-Alder (DA) Reaction 
have been used for dendrimer synthesis provided some of the 
problems inherent to these methods like the catalyst load might not 
be enough which has to be optimized precisely or the dendrimer 
might complex with the metallic portion of the catalyst has to be 
taken care of. Some novel methods like the Janus method, onion peel 
strategy etc. are also being developed. Click chemistry application 
using an effective coupling agent to conjugate the drug with the 
PEGylated PAMAM dendrimer to improve the polymer-drug 
coupling efficiency has been reported by Olga Yu. Zolotarskaya et al. 
(2015) [77, 78]. 
resulting in the doubling of the end groups with a reduced 
number of reaction steps. Here an orthogonal model of reaction 
happens between ‘A and D’ and ‘C and B’ specifically [76]. 
7. Lego chemistry: It is a direct method of synthesis involving 
two-branched monomers in which each quantitative step gives a 
corresponding generation (5 steps will give a fifth-generation G5 
dendrimer). The reactions will produce only eco-friendly 
by-products like sodium chloride, water, nitrogen, etc. Moreover, it 
is an economic as well as time-saving method [79]. 
Dendrimers have potential applications as drug delivery agents in 
CNS, oral, nasal, pulmonary, topical and transdermal drug delivery, 
gene delivery, vaccine delivery, as ophthalmic vehicles, in cancer 
treatment for targeting imaging as well as therapy such as 
photodynamic therapy (PDT), boron neutron capture therapy 
(BNCT), Gadolinium based (Gd) neutron capture therapy (GdNCT). 
They can also work as a useful tool in the area of diagnosis as 
molecular probes, X-ray contrast agents, MRI contrast agents, etc. 
Even though at the stage of infancy, dendrimers are expanding their 
applications to the biomedical field by its usage in tissue 
engineering, cell repair, blood substitution and cosmetics and 
personal care applications [80-82]. It is found that dendrimers are 
the single category of synthetic macromolecules that can be used as 
polymeric scaffolds to achieve biomimetic functions. Studies has 
been reported to show their mimicking capability of the surface 
structure of proteins requires in angiogenesis inhibition for its usage 
in antitumor systems, in biomimetic regeneration of Hydroxyapatite, 
which mimics the organic matrices induced biomineralization 
process in developing enamel and enhances the binding strength at 
the remineralization interface[83] and the collagen mimetic 
dendrimers [83-85]. 
There are many excellent reviews on dendrimers as CNS delivering 
agents of drug molecules and other therapeutic agents. In this 
article, we focus on the latest pharmaceutical application of 
dendrimers for the transport of drugs, nucleic acids, and 
proteins/peptides to the brain system that has happened in the 
years since 2014 [86-88].  
Recent studies on various CNS application of dendrimers  
1. Brain-specific targeting potential 
Targeting the drug to the site of action and minimizing its 
distribution to the rest of the body is the prime objective of any drug 
delivery system. This will reduce the required dose to get the same 
therapeutic action and in turn reduces the side effects. Targeting can 
be achieved via several means. The most acceptable and successful 
method is true to conjugate a specific ligand that has the binding 
capacity to the receptors and transporters present on the membrane 
to be crossed at the site of action [89, 90]. 
On the understanding that the generation 4 
polyamidoamine (PAMAM) dendrimers with hydroxyl terminal 
group (D4-OH) can penetrate the injured BBB and target the 
activated glia, A Sharma, JE Porterfield et al. (2018) was interested 
to know whether conjugating the targeting ligands would increase 
the uptake of dendrimers by the brain and other organs. Their study 
was based on the conjugation of mannose to the surface of 
multifunctional D4-OH since mannose receptors are typically 
over-expressed on injured microglia. The method for synthesis was 
orthogonal Cu(I)-catalyzed alkyne-azide cycloaddition (CuAAC) click 
chemistry, which was very efficient and required lesser atoms. The 
in vitro evaluation of the effect of mannose conjugation as a 
targeting ligand changed the dendrimer internalization process 
significantly, thus suggesting receptor-mediated endocytosis of 
mannose is preferable to non-specific fluid-phase endocytosis. The 
in vivo studies included the CNS uptake and of targeted and 
non-targeted biodistribution of fluorescently labelled dendrimers in 
a model of rabbit with maternal intrauterine inflammation-induced 
with cerebral palsy using fluorescence spectroscopy and confocal 
microscopy for quantification. Without any reduction in the quantity 
of dendrimer supplied to the injured glia in the brain, the 
distribution of the mannose conjugated dendrimer was varied 
throughout the body of the animal model, indicating that mannose 
conjugation can change the interaction of the dendrimer with all the 
body cells without affecting the inherent targeting ability to the 
inflammatory sites in the brain [91, 92]. 
Another recent study done for increasing the targetability of drugs 
towards the brain using dendrimers is the conjugation of PAMAM 
dendrimers with minocycline, a drug proven potent for neurological 
diseases. Minocycline has the inherent ability to penetrate the BBB 
but is required in large doses to attain the therapeutic concentration 
in the brain resulting in peripheral side effects. The innate stability 
of minocycline prevents it from chemical modifications. Thus to 
reduce the dose requirement by site-specific targeting, R Sharma, SY 
Kim et al. (2017) designed a drug dendrimer conjugate, namely 
hydroxyl-G6 PAMAM dendrimer–9-amino-minocycline conjugate 
(D-mino) and characterized it is in vitro efficiency and in vivo aiming 
capability. The poly(amidoamine) (PAMAM) generation-6 (G6) 
dendrimers with hydroxyl terminal groups was selected based on 
the finding that it can stay long in the circulation and can cross the 
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impaired BBB and they conjugated 9-amino-minocycline (mino) to 
the surface of the dendrimer through enzyme responsive linkages 
using a blend of mild copper-catalyzed azide-alkyne click reaction 
(CuAAC) and microwave energy. The in vitro release studies showed 
that there is no drug release at the physiological pH but a sustained 
release up to 8 d after an initial low release (below 10% till 48 h) at pH 
5.5 which simulates the lysosomal pH wherein the conjugate is taken 
up. Confocal microscopy and flow cytometry results presented a better 
cellular uptake of D-mino and further evaluation of anti-inflammatory 
and antioxidant activity in lipo-polysaccharides-activated murine 
microglial cells showed reduced production of inflammatory cytokine 
tumor necrosis factor α (TNF-α) and a significant reduction in 
oxidative stress by subsiding nitric oxide generation compared to the 
free drug. The invivo imaging studies with fluorescently labeled 
dendrimer conjugate (Cy5–D-mino) by systematic intravenous 
administration to suitable cerebral palsy induced rabbit kits and 
sacrificed after 24 h indicated the effective distribution of the 
dendrimer drug conjugate in the periventricular white matter areas of 
the corpus callosum and periventricular region which were most 
affected areas of the brain injury model with significant microglial 
activation. The satisfactory results of the study proved the potential of 
PAMAM dendrimers for effective drug targeting in neuroinflammatory 
conditions [93, 94]. 
H. K Patel et al. (2016) evaluated a comparative targeting potential 
of different ligands by developing dendritic nanoconjugates for the 
delivery of paclitaxel (PTX) to the cancerous site of the brain. They 
studied three ligands, namely Concanavalin A, Sialic acid, and 
glucosamine, which were separately conjugated to the paclitaxel 
loaded 5.0G poly(propyleneimine) (PPI) dendrimers. This was done 
based on the point that receptors of sialic acid and GLUTs transporters 
were overexpressed in BBB, which can be utilized as targeting 
possibilities [95]. The blood circulation time of the ligand conjugated 
dendritic nanoparticles and their half-lives were extended when 
compared to free PTX and PTX-PPI. The biodistribution studies gave 
significantly high brain concentration of paclitaxel from sialic acid 
anchored dendrimers (SPPI) than glucosamine anchored dendrimers 
(GPPI) and very negligible quantity by concanavalin A (ConA) 
anchored dendrimers (CPPI) but all of them could outstand the free 
drug and drug-loaded dendrimer. This accounts for the blocking of 
P-gp efflux system, which remained a major hurdle for the entry of 
PTX to the brain cells. This in turn increased the bioavailability of the 
drug in the CNS and all the three ligands in the order SPPI>GPPI>CPPI 
are efficient to bring an improved therapeutic outcome in treating 
brain cancer with paclitaxel [96]. 
2. Increasing the brain permeability of drugs via cationization 
with dendrimers 
Most of the drugs are reported to be poorly bioavailable in the brain 
due to its low permeability across the blood-brain barrier. 
Incorporating such small therapeutic molecules into the 
nanoparticles by employing adsorption, covalent bondage, or 
encapsulation can improve the brain concentration of drugs to a 
great extent [92]. Such an attempt of improving the permeability of 
the drug Citicholine which is found effective for the treatment of 
stroke by cationization of the drug-loaded bovine serum Albumin 
nanoparticles with G2 PAMAM dendrimers termed as dendrimer 
amplified albumin nanoparticles (dAA) was done by Pradhan D et al. 
(2019). The advantages of using PAMAM dendrimers over other 
cationization agents like ethylenediamine, hexamethylenediamine, 
PEI are that only a small amount of dendrimer is required for 
cationization as it has sufficient cationic amine groups in a single 
molecule and thereby reduce toxicity issues too. The permeability 
study using the in vitro BBB model was made of bEnd.3 cells proved 
that the rate of permeation was increased to thrice the rate of 
non-cationized albumin nanoparticles, which is accounted for the 
electrostatic interaction between the brain endothelial surface and 
the cationic groups in the dendrimer surface leading to cellular 
absorptive endocytosis. The drug release studies also showed an 
added advantage of the dAA nanoparticles that there is an increase 
in the release, which is pH-dependent. There is a slightly acidic pH at 
the disease site and at this reduced pH, the dendrimer grafted 
albumin nanoparticles could show increased cumulative percentage 
drug release at pH 5 than at normal physiologic pH 7.4 whereas the 
albumin nanoparticles showed the same release irrespective of the 
change in pH. Besides, unlike the commonly used cationization 
agents, there is no toxicity factor added to the nanoparticle which 
has been proved successfully through the MTT assay [97]. 
3. Application in foetal neurotherapy 
Certain infections like bacterial vaginosis, chlamydia, 
cytomegalovirus, syphilis, etc affecting women during their 
pregnancy can lead to cause life-threatening diseases to the 
newborns. It is better to control such infections at the foetal stage 
itself as early as possible by treating prenatally. Such a study was 
reported by using the PAMAM dendrimers by Zhang F et al. in 
maternal intrauterine inflammation-induced rabbit model with 
Cerebral Palsy. It is a chronic childhood condition that has the 
intrauterine infection as a major risk factor. They used neutral and 
anionic surface-modified PAMAM dendrimers using hydroxyl 
(D-OH) and carboxyl (D-COOH) terminal groups respectively and 
injected the dendrimer solutions intra-amniotically to study its 
placental barrier crossing and microglial targeting to reduce the 
neuroinflammation. The distribution studies showed that both D-OH 
and D-COOH enter fetal circulation while D-OH has better brain 
accumulation owing to its neutral surface charge density and 
D-COOH was constrained to the blood vessels. This study 
encourages to consider intra amniotic delivery of dendrimers as an 
effective targeting of fetal inflammation and associated neurological 
conditions. These findings give a futuristic hope for a translational 
therapy based on dendrimers to treat pediatric brain injuries [98]. 
4. Reducing the invasiveness of drug administration for CNS 
delivery 
The success of any CNS treatment is the reachability of the drug to 
the brain in its minimum dose with the least side effects. Being 
invasive might ensure the direct delivery of the drug to the site but 
the risks associated are beyond the benefits. The application of 
dendrimers to minimize the invasiveness was one of the major aims 
of the study conducted by B. Srinageshwar et al. (2017) by 
administration via the carotid artery in experimental animals like 
mice. This team also investigated a novel approach of using mixed 
surface dendrimers to reduce the toxicity issue which is one of the 
main drawbacks of conventional cationic dendrimers which refrain 
them from reaching the clinical studies. From the in vitro 
experiments, they could confirm the uptake of both the cationic 
amine dendrimers (G1-NH2 and G4-NH2
5. For protein and peptide delivery 
) and the mixed surface 
dendrimers (G1-90/10 and G4-90/10) using primary cortical 
culture. The results offer the novel dendrimers to be promising 
alternatives as carrier systems with much-reduced toxicity. For in 
vivo experiments, there were two methods of administration (1) 
transplanting the G4-90/10 into mice through the invasive 
intracranial injections into the striatum; and (2) less invasive 
dendrimer administration by intracarotid injection through the 
internal carotid artery. After analyzing the brains of the sacrificed 
animals 24-h and 1-week post-transplantations, it was confirmed 
that the G4-90/10 can cross the physiological barrier BBB when 
introduced through the carotid artery and confined within neurons 
and glial cells and was found to move through the corpus callosum a 
week after the intracranial injection. It was shown that the traveling 
cells were the glial cells that were infected with dendrimers by 
immunohistochemistry. Overall, the outcomes suggested that the 
mixed surface dendrimers can be used as a slightly invasive method 
to transport biomolecules for managing neurological disorders [99]. 
The delivery of therapeutic protein and peptide molecules for the 
treatment of many neurodegenerative diseases remains extremely 
challenging because of its rapid clearance from serum and very limited 
permeability to the brain. Even though BBB bypassing routes like 
intracerebroventricular (i. c. v.), intraparenchymal, intranasal (i. n.) or 
intrathecal (i. t.) have been proposed as direct delivery methods to the 
brain they show little positive results in practice. In the efforts to 
develop effective delivery systems, stands up the dendrimer approach. 
Pierpaolo Moscariello et al. (2018) designed a dendronized 
streptavidin (DSA) which was structurally identical to endogenous 
proteins. Fig. 2 shows the PAMAM dendrimers of two generations (G2 
and G3) with different positive charges were attached to the 
streptavidin core through biotin click chemistry [100].
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Fig. 2: The PAMAM dendrimers attached to the streptavidin core through biotin [101] 
 
The study successfully demonstrated the improved ability of the 
protein molecule to cross the BBB by transcytosis via the endosomal 
pathway with high biocompatibility proving a new flexible 
nanoplatforms for the delivery of biopharmaceuticals can be 
hopefully developed [102]. 
6. For Gene/Nucleic acid delivery 
APOPTIN gene delivery 
In the case of HIV-1 infections, gene-based therapy is found to be 
more cure effective than the antiretroviral drugs and its 
combinatorial therapy owing to the silencing of gene expression of 
the viral or host mRNA target using RNA interference. The delivery 
of RNAi therapeutics to the brain to attain the treatment goal is very 
challenging, obviously due to the difficulty to cross the BBB. siRNA is 
a promising strategy of therapy as it is synthesized chemically, has 
targeting specificity, and can be easily subjected to changes with the 
mutation of the virus without loss of potency. To find out an 
effective platform for the delivery of siRNA for the treatment of 
HIV-1 infection, M. J. Serramia et. al (2014) studied the possibility of 
using dendrimers for site-specific targeting. They could successfully 
prove that carbosilane dendriplexes of generation 2 made cationic in 
nature can improve the brain concentration of siRNA protected in 
the dendrimer by the in vivo imaging studies of the fluorescent 
labelled dendrimer administered as a retro-orbital injection to 
BALB/c mice. The cellular uptake of dendriplex was found to be 
double than the random siRNA by the human astrocytes and 
thereby, increased reduction of viral infectivity by blocking selected 
protein synthesis was attained [103-105]. 
SRL peptide for targeted gene delivery to the brain (2015) 
Application of peptides having an affinity towards the 
over-expressed molecules at the target site has been explored by 
Zhao J et al. in the work in which they conjugated the PEGylated 
PAMAM dendrimer with the peptide CREKA to promote improved 
residence time of the drug at the tumor site in the brain. This 
peptide molecule has an affinity towards the fibrin molecules which 
are overproduced in the brains of patients affected by Glioblastoma 
multiforme, one of the most life-threatening brain tumors [106]. The 
PAMAM dendrimers, when reduced in size, achieve the blood-brain 
barrier crossing ability and when further PEGylated, it can remain in 
the systemic circulation for a prolonged period with reduced 
cytotoxicity [107]. A similar work was reported by Jiang Y et. al but 
by using a different peptide, namely Pep-1, which can cross the 
tumor barrier through endocytosis mediated by interleukin 13 
receptor α2 (IL-13Rα2). The anticancer action of arsenic trioxide 
was improved almost four times compared to drug solution when a 
peptide RGDyC based on Arg-Gly-Asp amino acid sequence was 
conjugated to the drug-loaded modified PEG-PAMAM dendrimer. 
This accounts for the fact that the dendrimers, when conjugated 
with tumor homing peptides it can increase the effective brain 
concentration of the dendrimer resulting in improved therapeutic 
outcome [108, 109]. 
CONCLUSION 
There is a remarkable rise in the proportion of the population 
around the world being affected by various CNS disorders every 
year, especially with the aging population due to the increased life 
expectancy. In addition, the financial burden of the currently 
available treatments has stressed the need for effective drug 
delivery to the brain. The advances in nanotechnology presents the 
amazing potential of dendrimers as nanocarriers for brain delivery 
and some of the recent impeccable works done in this direction has 
been discussed in this article. Dendrimers become superior to other 
nanocarriers since they can permeate the BBB and be accessible to 
the brain following systemic circulation due to its unique 
characteristics. Their controllable nanosize, flexibility in designing 
numerous molecules via surface functionalization, thereby increasing 
targetability to the brain, ability to protect and deliver biomolecules 
like proteins, peptides, nucleotides, and genes promoting them as 
effective therapeutic and theranostic agents are the significant 
advantages of the dendrimers giving enormous scope for research in 
this area. However, a more extensive evaluation of the in vivo 
distribution and safety profile of dendrimers has to be done for 
bringing forth their reliability as nanocarriers. Despite all these 
recognized applications, the usage of dendrimers for CNS delivery is 
static in its embryonic stage and to date, none of the promoted 
dendrimer formulations has been reported for CNS therapy. Moreover, 
dendrimer synthesis is laborious even though they are commercially 
available nowadays which are ready for tuning to any desired feature 
and the balance between toxicity and biodegradability is highly 
dependent on the scaffold. Better biocompatibility, newer linker 
strategies, and wider options to transport biologicals and small 
molecules using dendrimers are the studies in the pipeline and the 
evolution of dendrimers as the next generation smart nanocarriers for 
CNS delivery is eagerly awaited for attaining future goals like the 
improved modulation of synaptic activity to provide higher neuronal 
functions in related pathologies such as epilepsy, schizophrenia, 
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